ZA202210356B - Method for treatment of neurological disorders using synaptic pathway training - Google Patents

Method for treatment of neurological disorders using synaptic pathway training

Info

Publication number
ZA202210356B
ZA202210356B ZA2022/10356A ZA202210356A ZA202210356B ZA 202210356 B ZA202210356 B ZA 202210356B ZA 2022/10356 A ZA2022/10356 A ZA 2022/10356A ZA 202210356 A ZA202210356 A ZA 202210356A ZA 202210356 B ZA202210356 B ZA 202210356B
Authority
ZA
South Africa
Prior art keywords
treatment
neurological disorders
synaptic pathway
training
pathway training
Prior art date
Application number
ZA2022/10356A
Other languages
English (en)
Inventor
Joseph Rustick
Original Assignee
Joseph Rustick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/827,546 external-priority patent/US20200222656A1/en
Application filed by Joseph Rustick filed Critical Joseph Rustick
Publication of ZA202210356B publication Critical patent/ZA202210356B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36021—External stimulators, e.g. with patch electrodes for treatment of pain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Hospice & Palliative Care (AREA)
  • Social Psychology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
ZA2022/10356A 2020-03-23 2022-09-19 Method for treatment of neurological disorders using synaptic pathway training ZA202210356B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/827,546 US20200222656A1 (en) 2016-10-18 2020-03-23 Method for treatment of depression using synaptic pathway training
PCT/US2021/022517 WO2021194796A1 (fr) 2020-03-23 2021-03-16 Méthode de traitement de troubles neurologiques à l'aide d'un entraînement de voie synaptique

Publications (1)

Publication Number Publication Date
ZA202210356B true ZA202210356B (en) 2023-02-22

Family

ID=77890584

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/10356A ZA202210356B (en) 2020-03-23 2022-09-19 Method for treatment of neurological disorders using synaptic pathway training

Country Status (7)

Country Link
EP (1) EP4126199A4 (fr)
BR (1) BR112022019234A2 (fr)
CA (1) CA3172981A1 (fr)
IL (1) IL296693A (fr)
MX (1) MX2022011862A (fr)
WO (1) WO2021194796A1 (fr)
ZA (1) ZA202210356B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230202978A1 (en) 2022-03-04 2023-06-29 Reset Pharmaceuticals, Inc. Co-crystal or salt

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9064036B2 (en) * 2008-04-24 2015-06-23 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
WO2016004396A1 (fr) * 2014-07-02 2016-01-07 Christopher Decharms Technologies pour entraînement d'exercice cérébral
WO2016061320A2 (fr) * 2014-10-15 2016-04-21 Rowan University Thérapie timber pour le trouble du stress post-traumatique
WO2017180589A1 (fr) * 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Dérivés de kétamine deutérés
US10596378B2 (en) * 2016-10-18 2020-03-24 Joseph Rustick Method for treatment of depression using synaptic pathway training
US20200222656A1 (en) * 2016-10-18 2020-07-16 Joseph Rustick Method for treatment of depression using synaptic pathway training
AU2019262197A1 (en) * 2018-05-04 2020-11-26 Perception Neuroscience, Inc. Methods of treating substance abuse

Also Published As

Publication number Publication date
EP4126199A1 (fr) 2023-02-08
CA3172981A1 (fr) 2021-09-30
WO2021194796A1 (fr) 2021-09-30
BR112022019234A2 (pt) 2022-11-08
EP4126199A4 (fr) 2024-04-10
IL296693A (en) 2022-11-01
MX2022011862A (es) 2023-02-16

Similar Documents

Publication Publication Date Title
IL289840A (en) Methods and products for the treatment of digestive system disorders
EP4013403A4 (fr) Méthodes de traitement de troubles psychologiques et cérébraux
EP4010072A4 (fr) Traitement de troubles du système nerveux central
IL276604B (en) A device for treating neurological disorders by electrical stimulation and a method for processing nerve signals collected by the device
ZA202210356B (en) Method for treatment of neurological disorders using synaptic pathway training
IL288574A (en) Oligonucleotides and methods for use in the treatment of neurological diseases
EP4185382A4 (fr) Méthodes de traitement de troubles respiratoires aigus
IL275528A (en) Preparations and methods for the treatment of neurological disorders including dementia
IL294594A (en) Methods of treating pemphigus
EP4100002A4 (fr) Traitement de troubles neurologiques avec des avermectines
EP4210755A4 (fr) Compositions et méthodes de traitement de troubles neurologiques
EP4171564A4 (fr) Méthodes de traitement de troubles neurodéveloppementaux
GB202210740D0 (en) System and method for low rank training of neural networks
EP4188368A4 (fr) Compositions et méthodes de traitement de maladies et de troubles
EP4248212A4 (fr) Méthodes de traitement de maladies et troubles pulmonaires
EP4208159A4 (fr) Compositions et méthodes de soulagement d'affections et de troubles neurologiques
IL308669A (en) Methods for the treatment of disorders related to mitochondria
EP3911348A4 (fr) Méthode de traitement de maladie du système nerveux central
IL304628A (en) Treatment of skin disorders
GB202004498D0 (en) Activity-dependent gene therapy for neurological disorders
EP4135661A4 (fr) Compositions et méthodes de traitement de troubles neurologiques
EP4229035A4 (fr) Administration intranasale de suramine pour le traitement de troubles du système nerveux
IL289221A (en) Compounds for the treatment of vision disorders
AU2022233762A1 (en) Method of treating diseases using gremlin1 antagonists
EP4096680A4 (fr) Oligonucléotides antisens pour le traitement de troubles neurologiques